Impact of Pneumococcal Conjugate Vaccine Administration in Pediatric Older Age Groups in Low and Middle Income Countries: A Systematic Review.
Pneumococcal conjugate vaccine (PCV) is included in the World Health Organization's routine immunization schedule and is recommended by WHO for vaccination in high-risk children up to 60 months. However, many countries do not recommend vaccination in older age groups, nor have donors committed...
Main Authors: | Kimberly Bonner, Emily Welch, Kate Elder, Jennifer Cohn |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4557974?pdf=render |
Similar Items
-
Pneumococcal conjugate vaccine implementation in middle-income countries
by: Tricarico, Serena, et al.
Published: (2017) -
Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country.
by: Gabriela García Gabarrot, et al.
Published: (2014-01-01) -
Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.
by: Manuel Alexander Haasis, et al.
Published: (2015-01-01) -
The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries.
by: Stefan Flasche, et al.
Published: (2015-06-01) -
How Are New Vaccines Prioritized in Low-Income Countries? A Case Study of Human Papilloma Virus Vaccine and Pneumococcal Conjugate Vaccine in Uganda
by: Lauren Wallace, et al.
Published: (2017-12-01)